Illumina (NASDAQ:ILMN) Announces Earnings Results

Illumina (NASDAQ:ILMN) released its quarterly earnings data on Thursday. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05, RTT News reports. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.28% and a negative net margin of 28.71%. The business’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the firm posted $0.08 earnings per share.

Illumina Price Performance

ILMN opened at $117.93 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The company’s 50 day moving average is $130.03 and its 200-day moving average is $127.02. Illumina has a 1-year low of $89.00 and a 1-year high of $213.91.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. Robert W. Baird lifted their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Finally, StockNews.com lowered Illumina from a “buy” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $165.10.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.